In today's world of frequent population movements, new infectious diseases can spread rapidly across borders. Traditional vaccines and treatments struggle to keep up with the emergence and spread of new infections, requesting new technological platforms for vaccines and therapeutics. Protein Immuno-Engineering Laboratories, Inc., a startup venture from Tokyo University of Agriculture and Technology, provides a technological platform called PI-Bio(πBIO) to develop preventive and therapeutic drugs to prevent large-scale viral outbreaks at an early stage. PI-Bio stands for Protein Immuno-engineering Biologics. PI-Bio integrates the latest knowledge and techniques in protein engineering, bioinformatics, and immunology. It is a game-changer in the fight against both sporadic and seasonal epidemic viruses and their mutant strains. It empowers the preparation of vaccine seeds and isolation of monoclonal antibodies in a remarkably short period of 1.5 to 2 years. Moreover, the manufacturing process of vaccines designed by PI-Bio is efficient and highly environmentally friendly.
Our company is committed to fostering long-term partnerships with vaccine and drug development companies and major pharmaceutical manufacturers. It provides a collaborative environment where our partners can leverage our unique technological platform to accelerate their research and development processes and, ultimately, contribute to global health security.